Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

SARS-CoV-2-RNA viremia is a robust marker of critical illness in COVID-19

A new study by a large team of Spanish researchers and published on the preprint server medRxiv* in August 2020 reports that the presence of viral RNA in the blood is a useful marker of impending acute disease and can help triage COVID-19 disease patients who will require hospital care.

1 Sep 2020

SARS-CoV-2 is more resistant on surfaces in spring and autumn than in summer

In a recent bioRxiv* preprint paper, researchers from Kansas State University demonstrate astonishing persistence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on various types of surfaces – especially under spring/fall climate conditions.

1 Sep 2020

Promising new candidate 'virus-like particle' vaccine for COVID-19

Researchers in the UK and Taiwan have demonstrated the potential of a new candidate vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the virus responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

1 Sep 2020

Silicon nitride shows potent SARS-CoV-2 neutralization capability

A new study published on the preprint server bioRxiv* in August 2020 shows that the man-made compound silicon nitride, which is used in medical implants and high mechanical performance engineering applications, is capable of inactivating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at varying concentrations without causing cell cytotoxicity. This finding should be investigated to develop disinfectants to clear the virus from surfaces, preventing its spread.

1 Sep 2020

Spike ferritin nanoparticles show potential as SARS-CoV-2 vaccine

Now, a new study published on the preprint server bioRxiv* in August 2020 reports the induction of neutralizing antibodies in mice by a single dose of a ferritin nanoparticle-based vaccine containing the spike protein.

1 Sep 2020

Study: Impact of COVID-19 virus goes far beyond the pulmonary system

Described as a novel, "once-in-a-century" disease, COVID-19 research is evolving to include a growing body of evidence that the virus's impact goes far beyond the pulmonary system.

1 Sep 2020

New data can help create more accurate models to describe the spread of COVID-19

According to a linguist from RUDN University, the number of COVID-19 cases in a country might be related to the existence of aspirated consonants in its main language of communication.

1 Sep 2020

Scientists explain why SARS-CoV-2 targets multiple organs

Now, a team of researchers at LSU Health New Orleans’ Neuroscience Center of Excellence and School of Medicine has explained the gateway receptor for SARS-CoV-2 and how it leads to the emergence of many complications as it targets many parts of the body.

31 Aug 2020

Majority of U.S. COVID-19 fatalities had underlying medical conditions

Early on in the coronavirus disease (COVID-19) pandemic, there was little data on the virus and how it affects the body. As the virus spread across the globe, data showed that some people were at a higher risk of developing severe disease and dying from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

31 Aug 2020

A nanoscaffolding approach for rapid design of highly immunogenic SARS-CoV-2 vaccines

A research group from Slovenia, Switzerland, and Germany shows how nanoscaffolded assemblies may neutralize interaction between the SARS-CoV-2 spike protein and cell receptor, providing adequate protection in a surrogate infection assay and warranting the advance of such platforms in the pursuit for the effective vaccine.

31 Aug 2020

Vaccine reduces race-based pneumococcal disease disparities

In a major public health success, the introduction of pneumococcal conjugate vaccine PCV13, or Prevnar 13, in 2010 in the United States is associated with reduction in socioeconomic disparities and the near elimination of Black-white-based racial disparities for invasive pneumococcal disease.

31 Aug 2020

Study identifies effective treatment for severe COVID-19 patients

As countries around the world race to develop a vaccine for SARS-CoV-2, the virus responsible for COVID-19, researchers are working to understand exactly how it causes the myriad of symptoms that seem to linger long after active viral infection.

31 Aug 2020

Study examines whether asthma is a significant risk factor for severe COVID-19

A new research letter published online in the Annals of the American Thoracic Society examines whether asthma is a significant risk factor for developing COVID-19 that is severe enough to warrant hospitalization and intubation.

31 Aug 2020

IL-6 signaling blockade can alleviate severe COVID-19

A team of researchers led by Osaka University find an overlap in the pathogenesis of cytokine release syndrome and COVID-19, and show that the symptoms of both can be alleviated by IL-6 signaling blockade

31 Aug 2020

ESC publishes treatment guidelines for non-ST-segment elevation acute coronary syndrome

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

31 Aug 2020

Serum protein shows therapeutic value against severe COVID-19-like features in mouse model

A new study published on the preprint server bioRxiv* in August 2020 reports the disease-mitigating effects of a serum protein called serum amyloid P (SAP) in mice exposed to a peptide that mimics the clinical signs of severe COVID-19 in humans.

30 Aug 2020

Evidence of SARS-CoV-2 spreading in an airplane toilet

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease (COVID-19), is still actively spreading like wildfire, with nearly 300,000 new infections reported daily across the globe. Early on in the outbreak in China, scientists said that the virus could spread through respiratory droplets, when a person coughs, sneezes, or speaks.

30 Aug 2020